Superparamagnetic Iron Oxide Nanoparticles for Delivery of Tissue Plasminogen Activator
Superparamagnetic Iron Oxide Nanoparticles for Delivery of Tissue Plasminogen Activator
复制标题
DOI：
10.1166/jnn.2011.3953
复制
发表时间：
2011-12-01
影响因子：
--
通讯作者：
Lu, Yu-Jen
中科院分区：
文献类型：
--
作者：
Chen, Jyh-Ping;Yang, Pei-Chin;Lu, Yu-Jen
合成了羧甲基葡聚糖（CMD）修饰的磁性纳米粒子（MNP），并通过傅里叶变换红外光谱、透射电子显微镜、超导量子干涉装置、动态光散射、热重分析和X射线衍射对其进行了表征。颗粒表面的 CMD 涂层提供丰富的 COOH 官能团，可与溶栓药物重组组织纤溶酶原激活剂 (rtPA) 结合。较高CMD/MNP比例制备的CMD涂层MNP（CMD-MNP）具有较高的CMD含量、较少的铁含量、较多的COOH表面基团、较小的流体动力学直径和较小的饱和磁化强度。使用乳酸脱氢酶测定的体外生物相容性研究表明 CMD-MNP 不会引起细胞毒性。通过将 0.25 mg rtPA 与 5 mg CMD-MNP 接触可以实现最佳载药量，其中所有 rtPA 都固定在磁性纳米载体上，并完全保留其溶栓活性。
Magnetic nanoparticle (MNP) modified by carboxymethyl dextran (CMD) was synthesized and characterized by Fourier transform infrared spectroscopy, transmission electron microscopy, superconducting quantum interference device, dynamic light-scattering, thermogravimetric analysis, and X-ray diffraction. CMD coating on the particle surface provides abundant COOH functional groups for conjugating with a thrombolytic drug, recombinant tissue plasminogen activator (rtPA). CMD-coated MNP (CMD-MNP) prepared with higher CMD/MNP ratios had higher CMD content, less iron content, more COOH surface groups, smaller hydrodynamic diameter, and smaller saturation magnetization. The in vitro biocompatibility study using lactate dehydrogenase assays indicated that CMD-MNP elicited no cell cytotoxicity. The optimum drug loading could be achieved by contacting 0.25 mg rtPA with 5 mg CMD-MNP where all rtPA is immobilized to the magnetic nanocarrier with full retention of its thrombolytic activity.